000141421 001__ 141421
000141421 005__ 20240229105127.0
000141421 0247_ $$2doi$$a10.1002/ijc.31623
000141421 0247_ $$2pmid$$apmid:29923180
000141421 0247_ $$2ISSN$$a0020-7136
000141421 0247_ $$2ISSN$$a1097-0215
000141421 0247_ $$2altmetric$$aaltmetric:51240397
000141421 037__ $$aDKFZ-2018-01927
000141421 041__ $$aeng
000141421 082__ $$a610
000141421 1001_ $$0P:(DE-He78)9a183bfc8348c1db81a0ecf1458d0708$$aGraf, Mirja$$b0$$eFirst author$$udkfz
000141421 245__ $$aPre-diagnostic plasma concentrations of Fibrinogen, sGPIIb/IIIa, sP-selectin, sThrombomodulin, Thrombopoietin in relation to cancer risk: Findings from a large prospective study.
000141421 260__ $$aBognor Regis$$bWiley-Liss$$c2018
000141421 3367_ $$2DRIVER$$aarticle
000141421 3367_ $$2DataCite$$aOutput Types/Journal article
000141421 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1542808366_32105
000141421 3367_ $$2BibTeX$$aARTICLE
000141421 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000141421 3367_ $$00$$2EndNote$$aJournal Article
000141421 520__ $$aWhile enhanced platelet activation may drive cancer progression and metastases, less is known about its role in early cancer development. Thus, we evaluated whether pre-diagnostic biomarkers of platelet activation and coagulation are related to the risks of common cancers in the prospective EPIC-Heidelberg Study using a case-cohort design. Levels of fibrinogen, soluble glycoprotein (sGP) IIb/IIIa, soluble P-selectin (sP-selectin), soluble thrombomodulin (sTM), and thrombopoietin (TPO) were measured in baseline plasma samples of a random subcohort (n = 2,480) and incident cases of breast (n = 605), prostate (n = 543), and colorectal cancer (n = 249). Multivariable Cox regression models revealed no statistically significant associations between biomarker concentrations and any of the cancer endpoints. Subgroup analyses showed a significant inverse relationship between TPO and colorectal cancer among men, with a hazard ratio (HR, highest vs. lowest quartile) of 0.60 (95% confidence interval: 0.37,0.95), whereas no significant association was observed among women. With regard to fibrinogen levels and breast cancer risk, there was a significant positive association among nulliparous women (HR: 2.53 [95% CI: 1.21, 5.30]), but not among parous women. Overall, our data suggest that enhanced platelet activation and a pro-coagulative state may not be related to increased risks of common cancers, although studies on other potential biomarkers of platelet activation and further cancer types are needed. Findings from our subgroup analyses require further investigation, as potential underlying mechanisms are not known.
000141421 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000141421 588__ $$aDataset connected to CrossRef, PubMed,
000141421 7001_ $$0P:(DE-He78)fd4ffe2a3f08e0158b82400acd6716be$$aSookthai, Disorn$$b1$$udkfz
000141421 7001_ $$0P:(DE-He78)79ab945544e5bc017a2317b6146ed3aa$$aJohnson, Theron Scot$$b2$$udkfz
000141421 7001_ $$0P:(DE-He78)ceb74219d144ab5760a228e71440c5ca$$aSchübel, Ruth$$b3$$udkfz
000141421 7001_ $$0P:(DE-HGF)0$$aMaldonado, Sandra González$$b4
000141421 7001_ $$0P:(DE-HGF)0$$aPletsch-Borba, Laura$$b5
000141421 7001_ $$0P:(DE-He78)fb68a9386399d72d84f7f34cfc6048b4$$aKatzke, Verena$$b6$$udkfz
000141421 7001_ $$aBugert, Peter$$b7
000141421 7001_ $$0P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f$$aHoffmeister, Michael$$b8$$udkfz
000141421 7001_ $$0P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aKaaks, Rudolf$$b9$$udkfz
000141421 7001_ $$0P:(DE-He78)0907a10ba1dc8f53f04907f54f6fdcfe$$aKühn, Tilman$$b10$$eLast author$$udkfz
000141421 773__ $$0PERI:(DE-600)1474822-8$$a10.1002/ijc.31623$$gVol. 143, no. 11, p. 2659 - 2667$$n11$$p2659 - 2667$$tInternational journal of cancer$$v143$$x0020-7136$$y2018
000141421 909CO $$ooai:inrepo02.dkfz.de:141421$$pVDB
000141421 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)9a183bfc8348c1db81a0ecf1458d0708$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000141421 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)fd4ffe2a3f08e0158b82400acd6716be$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000141421 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)79ab945544e5bc017a2317b6146ed3aa$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000141421 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)ceb74219d144ab5760a228e71440c5ca$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000141421 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000141421 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000141421 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)fb68a9386399d72d84f7f34cfc6048b4$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000141421 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000141421 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000141421 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)0907a10ba1dc8f53f04907f54f6fdcfe$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000141421 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000141421 9141_ $$y2018
000141421 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000141421 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000141421 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000141421 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000141421 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bINT J CANCER : 2017
000141421 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000141421 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000141421 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000141421 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000141421 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000141421 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000141421 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bINT J CANCER : 2017
000141421 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lEpidemiologie von Krebserkrankungen$$x0
000141421 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lKlinische Epidemiologie und Alternsforschung$$x1
000141421 980__ $$ajournal
000141421 980__ $$aVDB
000141421 980__ $$aI:(DE-He78)C020-20160331
000141421 980__ $$aI:(DE-He78)C070-20160331
000141421 980__ $$aUNRESTRICTED